On June 28, 2020, the clinical application of CNBG-VIROGIN's first oncolytic virus drug was accepted by the NMPA.

In 2015, the FDA approved the only oncolytic virus therapy so far-the modification of herpes simplex virus T-vec, opening a new chapter in oncolytic virus therapy.

At present, oncolytic viruses have been equipped with engineered wings, which combine the expression of IL-12, PD-1 antibody, GM-CSF, etc. to further enhance the immune response and turn cold tumors into hot tumors.

There are currently six oncolytic virus drug declarations in China, including Binhui Biologics, Tasly, Innovate, Weirongte, Binhui Biologics and CNBG-VIROGIN. Among them, Fonova and Inomicro adopt the strategy of PD-1/PD-L1 pathway inhibitor and IL-12 (Fanogym also expresses IL-15) cytokine in the engineering transformation to maximize the enhancement Immune effects of oncolytic viruses.

Binhui Biology founder Liu Binlei is the main inventor of T-vec. In 2018, Lepu Medical exclusively led Binhui Biology’s 110 million yuan A round of financing. Binhui Bio-Oncolytic Virus recombinantly expresses GM-CSF to enhance the immune effect. Tasly Oncolytic Virus issued shares in Transgene for $48 million in stock exchange, and obtained two drugs, T601 and T101. Among them, T601 is a vaccinia virus expressing the suicide gene FCU1. Weirongte was founded by talents returning from the United States and the Third University, dedicated to the development of oncolytic viruses. In addition, Hengrui Medicine obtained Oncolys' oncolytic adenovirus OBP-301 with an advance payment of USD 500,000 in 2016 with a milestone amount of RMB 1.02 billion. In addition, many pharmaceutical companies such as Anke Biology and Li's Pharmaceutical Factory also have oncolytic virus drugs.

Summarize

The combination of oncolytic viruses with PD-1 is currently an important research direction. The development of a new generation of oncolytic viruses in China is quite innovative. By installing oncolytic viruses to express PD-1/PD-L1 antibodies and IL-12 or IL -15 cytokine, maximizing the immune effect of oncolytic virus.

Dr. Jia Weiguo, the co-founder and chief scientist of Fonogym Bio, is a senior oncolytic virus research expert. In 2015, Fonogym Biotech reached a cooperation with Johnson & Johnson Innovation Platform to promote the development of oncolytic virus drugs carrying immune stimulating factors. The IL12/15-PDL1B oncolytic virus declared this time should be the innovative result of Fonogym Bio.

Source: Armstrong Biopharmaceutical Information

Disclaimer: Please contact us if it involves content, copyright or other issues.